Literature DB >> 2083255

Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells.

M R Smith1, M Jaramillo, Y L Liu, T E Dever, W C Merrick, H F Kung, N Sonenberg.   

Abstract

Several polypeptide factors that are essential for the initiation of protein synthesis bind to eukaryotic mRNAs and facilitate the formation of ribosome initiation complexes. Purified mRNA-binding translation initiation factors were microinjected into quiescent NIH 3T3 cells to study the possible growth-promoting role of these factors in living cells. We report that recombinant eIF-4E and rabbit reticulocyte eIF-4F induce a dose-dependent increase of DNA synthesis and morphologically transform NIH 3T3 cells. These results suggest that polypeptides involved in activating the rate-limiting step of protein synthesis (initiation complex formation) can be mitogenic and oncogenic when overexpressed in a cell by direct injection. Thus, eIF-4E and eIF-4F represent a class of proto-oncogenic proteins that is cytoplasmic, is involved in protein synthesis initiation, and is distinct from the proto-oncogenes that have been identified previously.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083255

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  32 in total

Review 1.  Mechanism and regulation of eukaryotic protein synthesis.

Authors:  W C Merrick
Journal:  Microbiol Rev       Date:  1992-06

2.  Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.

Authors:  Jonathan H Schatz
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

3.  Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation.

Authors:  W K Miskimins; G Wang; M Hawkinson; R Miskimins
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

4.  MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.

Authors:  Michal Grzmil; Roland M Huber; Daniel Hess; Stephan Frank; Debby Hynx; Gerald Moncayo; Dominique Klein; Adrian Merlo; Brian A Hemmings
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

5.  Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest.

Authors:  Honglin Luo; Jingchun Zhang; Frank Dastvan; Bobby Yanagawa; Michael A Reidy; Huifang M Zhang; Decheng Yang; Janet E Wilson; Bruce M McManus
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.

Authors:  Nina Ilic; Tamara Utermark; Hans R Widlund; Thomas M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

7.  Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc.

Authors:  V A Polunovsky; I B Rosenwald; A T Tan; J White; L Chiang; N Sonenberg; P B Bitterman
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

8.  Selective modification of eukaryotic initiation factor 4F (eIF4F) at the onset of cell differentiation: recruitment of eIF4GII and long-lasting phosphorylation of eIF4E.

Authors:  Sandrine Caron; Martine Charon; Elisabeth Cramer; Nahum Sonenberg; Isabelle Dusanter-Fourt
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts.

Authors:  A Lazaris-Karatzas; N Sonenberg
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

10.  The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization.

Authors:  Gert C Scheper; Josep L Parra; Mary Wilson; Barbara Van Kollenburg; Alfred C O Vertegaal; Ze-Guang Han; Christopher G Proud
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.